Abstract | OBJECTIVE: DESIGN: SETTING: Pediatric patients were in the cardiac intensive care unit and adult patients were in a tertiary-care hospital. PATIENTS: INTERVENTIONS: Dosages of iNO were 2-60 ppm. The duration of therapy ranged from 23 to 188 hrs in group 1 and 29 to 108 hrs in group 2. MEASUREMENTS AND MAIN RESULTS: Arterial blood was obtained for the measurement of ET-1 levels before and during iNO therapy and 24 hrs after iNO withdrawal. Group 1 mean ET-1 levels increased to 127% of baseline by 12 hrs of iNO, remained elevated at 48 hrs (p < .05), then decreased to 71% of iNO levels 24 hrs after withdrawal (p < .01). Group 2 ET-1 levels increased to 147%, and 137% of baseline at 12 and 24 hrs of iNO therapy, then fell to 68% of baseline within 24 hrs of discontinuing iNO. ET-1 levels in group 3 decreased after surgery (p < .05). CONCLUSIONS: These data suggest that iNO increased plasma ET-1 levels, which subsequently decreased when iNO was discontinued. Increased circulating ET-1 levels might contribute to rebound pulmonary hypertension upon iNO withdrawal.
|
Authors | Jeffrey M Pearl, David P Nelson, Jenni L Raake, Peter B Manning, Steven M Schwartz, Lisa Koons, Thomas P Shanley, Hector R Wong, Jodie Y Duffy |
Journal | Critical care medicine
(Crit Care Med)
Vol. 30
Issue 1
Pg. 89-93
(Jan 2002)
ISSN: 0090-3493 [Print] United States |
PMID | 11902294
(Publication Type: Journal Article)
|
Chemical References |
- Endothelin-1
- Vasodilator Agents
- Nitric Oxide
|
Topics |
- Administration, Inhalation
- Adult
- Aged
- Endothelin-1
(blood)
- Humans
- Hypertension, Pulmonary
(drug therapy, etiology)
- Infant
- Infant, Newborn
- Middle Aged
- Nitric Oxide
(administration & dosage, pharmacology)
- Substance Withdrawal Syndrome
- Vasodilator Agents
(administration & dosage, pharmacology)
|